Neuraxis stock hits 52-week low at $1.98 amid market challenges

Published 03/04/2025, 16:12
Neuraxis stock hits 52-week low at $1.98 amid market challenges

In a challenging market environment, Neuraxis Inc. (NRXS) stock has touched a 52-week low, falling to $1.98. The small-cap biopharmaceutical company, valued at $15.51 million and specializing in developing treatments for central nervous system disorders, has seen its shares struggle significantly over the past year. According to InvestingPro data, despite maintaining impressive gross profit margins of 86.5%, the company is currently unprofitable and burning through cash rapidly. Investors have witnessed a notable decline in the value of their holdings, with Neuraxis stock experiencing a 1-year change of -32.58%. This downturn reflects broader market trends and investor sentiment, as the company navigates through a complex healthcare landscape and competitive pressures. The current price level marks the lowest point for Neuraxis stock in the last year, underlining the need for strategic initiatives to bolster investor confidence and company growth. InvestingPro analysis suggests the stock is currently fairly valued, with analysts setting a target price of $4.75. Discover more insights and 6 additional ProTips for NRXS in the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

In other recent news, Neuraxis Inc. reported a strong performance in the fourth quarter of 2024, with revenue increasing by 43% year-over-year to $761,000. The company’s full-year revenue reached $2.7 million, reflecting a 9% increase from the previous year. Neuraxis also improved its net loss by 73% in Q4 compared to the same period last year, with an operating loss of $1.5 million. Notably, the company has expanded its FDA approvals and market reach, a development that could potentially drive future growth. Analysts have noted that Neuraxis is targeting cash flow breakeven, with expectations for revenue acceleration in 2025 and 2026, driven by the introduction of a second-generation IVStim device. Additionally, Neuraxis received a Category One CPT code, effective January 2026, which is expected to streamline billing and reimbursement processes. The company is also focusing on expanding insurance coverage, which has increased from 4 million to 51 million covered lives. These recent developments suggest that Neuraxis is positioning itself for significant growth in the coming years.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.